Securities code: Xiamen Amoytop Biotech Co.Ltd(688278) securities abbreviation: Xiamen Amoytop Biotech Co.Ltd(688278) Announcement No.: 2022014 Xiamen Amoytop Biotech Co.Ltd(688278)
Special report on the deposit and actual use of raised funds in 2021
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal responsibility for the authenticity, accuracy and integrity of its contents according to law.
Xiamen Amoytop Biotech Co.Ltd(688278) (hereinafter referred to as the “company”) in accordance with the relevant provisions of the China Securities Regulatory Commission, such as the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds by listed companies, the Listing Rules of the science and Innovation Board of Shanghai Stock Exchange, and the guidelines for the self-discipline supervision of listed companies on the science and Innovation Board of Shanghai Stock Exchange No. 1 – standardized operation, The deposit and actual use of the raised funds in 2021 are reported as follows:
1、 Basic information of raised funds
(I) actual amount of raised funds and receipt of funds
Approved by the reply on Approving the registration of Xiamen Amoytop Biotech Co.Ltd(688278) initial public offering (zjxk [2019] No. 2828) of China Securities Regulatory Commission and approved by the “self regulatory decision [2020] No. 21” of Shanghai Stock Exchange, the company issued 46.5 million RMB ordinary shares (A shares) to the public for the first time, with an issue price of 8.24 yuan per share, and the total funds raised this time was 383.16 million yuan, According to relevant regulations, after deducting the issuance expenses of 527137 million yuan, the net amount of funds actually raised was 3304463 million yuan. All the above raised funds have been received on January 13, 2020. Rongcheng Certified Public Accountants (special general partnership) has verified the receipt of funds and issued the capital verification report (Rongcheng Yan Zi [2020] No. 361z0003). The company has carried out special account storage management for the above raised funds. (II) use of raised funds
As of December 31, 2021, the company has used a total of 245488100 yuan of raised funds (including 1927744 million yuan of raised investment projects and 527137 million yuan of issuance expenses), 9.3355 million yuan of interest income, 50 thousand yuan of handling expenses, and the balance of raised funds is 14702400 yuan (including 60 million yuan of financial products that are not due).
(I) construction of raised funds management system
In order to standardize the use and management of raised funds, the company has formulated the management system of raised funds, which has made clear provisions on the storage, use and supervision of raised funds. In the management of raised funds, the company strictly abides by the requirements of laws, regulations and normative documents such as the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds by listed companies and the guidelines for the self discipline supervision of listed companies on the science and Innovation Board of Shanghai Stock Exchange No. 1 – standardized operation, and follows the principles of standardization, safety, efficiency and transparency.
(II) performance of tripartite supervision agreement for raised funds
On January 13, 2020, the company signed the tripartite supervision agreement on the special account storage of raised funds with the sponsor Sinolink Securities Co.Ltd(600109) and the bank with the special account for the storage of raised funds. The supervision agreement defines the rights and obligations of all parties, and the main terms of the agreement are not significantly different from the tripartite supervision agreement (model) on the special account storage of raised funds of Shanghai Stock Exchange. During the reporting period, all parties to the agreement performed their duties in accordance with the provisions of the regulatory agreement. (III) storage of raised funds in special account
As of December 31, 2021, the deposit of the company’s special account for raised funds is as follows:
Name of account opening bank: special account for raised funds of raised funds investment project
Account balance of name account (10000 yuan)
China Merchants Bank Co.Ltd(600036) shares 59290262711 protein drug production expansion
Xiamen Branch 0508 Jianhe R & D center construction project 404373 Xiamen tezhenhai sub branch project
Baobio China China Construction Bank Corporation(601939) shares 35150198110
Engineering Co., Ltd. Xiamen 1 Shenzhen Tellus Holding Co.Ltd(000025) 02 new drug R & D project 415278 Haicang sub branch
The company Industrial Bank Co.Ltd(601166) shares have clinical treatment of chronic hepatitis B
Xiamen Haicang 12994010010503.73 sub branch 0357161 research project
Total 870024
Note: as of December 31, 2021, the company used some idle raised funds for cash management, and the amount not yet due was 60 million yuan.
3、 Actual use of raised funds in 2021
(I) use of funds for projects invested with raised funds
During the reporting period, the actual use of the company’s raised funds is detailed in Schedule 1 “comparison table of the use of raised funds in 2021”.
(II) early investment and replacement of raised investment projects
On March 27, 2020, the company held the 14th meeting of the 7th board of directors and the 10th meeting of the 7th board of supervisors respectively, deliberated and approved the proposal on replacing the self raised funds invested in advance with the raised funds, and agreed to use the raised funds of 698005 million yuan to replace the self raised funds of the pre invested projects and the paid issuance expenses. The replacement work does not change the purpose of the company’s raised funds in a disguised manner, and the replacement time is less than 6 months from the arrival time of the raised funds, which meets the regulatory requirements. The independent directors and the recommendation institution of the company have expressed their explicit consent to the above matters. Rongcheng Certified Public Accountants (special general partnership) verified the above replacement matters and issued the verification report on Xiamen Amoytop Biotech Co.Ltd(688278) using self raised funds to invest in raised funds investment projects in advance and pay issuance expenses (Rongcheng zhuanzi [2020] No. 361z0167).
(III) temporary replenishment of working capital with idle raised funds
During the reporting period, the company did not temporarily supplement working capital with idle raised funds.
(IV) cash management of raised funds
On August 24, 2021, the company held the 23rd Meeting of the 7th board of directors and the 16th meeting of the 7th board of supervisors respectively, deliberated and approved the proposal on using some idle raised funds for cash management, and agreed that the company would use the idle raised funds with a maximum amount of no more than 150 million yuan (including this amount) for cash management in a timely manner without affecting the normal use of the raised funds, The authorization period is 12 months from the date of deliberation and approval by the board of directors (Announcement No.: 2021021). The independent directors and the recommendation institution of the company have expressed their explicit consent.
During the reporting period, the company used idle raised funds for cash management as follows:
Unit: RMB 10000
As of the reporting date, serial number, product name, amount, value date, maturity date, 2022.3.30 status
1 China China Construction Bank Corporation(601939) Xiamen structured deposit 3 China Vanke Co.Ltd(000002) 02011.162021.1.4 Haicang sub branch has been redeemed on schedule
2 China Industrial Securities Co.Ltd(601377) Co., Ltd. financial products of securities companies 2 China Vanke Co.Ltd(000002) 02011.242021.1.11 the company has been redeemed on schedule
3 Industrial Bank Co.Ltd(601166) Xiamen Haicang structured deposit 500. Zhejiang Jingxin Pharmaceutical Co.Ltd(002020) 12.7 2021.1.6 redeemed sub branch on schedule
4 China Galaxy Securities Co.Ltd(601881) securities company financial products 5 China Vanke Co.Ltd(000002) 02012.112021.1.11 the limited company has been redeemed on schedule
5. China China Construction Bank Corporation(601939) Xiamen structured deposit 2 China Vanke Co.Ltd(000002) 02012.302021.1.28 Haicang sub branch has been redeemed on schedule
As of the reporting date, serial number, product name, amount, value date, maturity date, 2022.3.30 status
6 China Industrial Securities Co.Ltd(601377) Co., Ltd. financial products of securities companies 35 Shenzhen Zhongheng Huafa Co.Ltd(000020) 2012.302021.3.1 the company has been redeemed on schedule
7 China Merchants Bank Co.Ltd(600036) Xiamen branch bank financial product 400000 redeemed with Zhenhai sub branch redeemed on January 5, 2021
Xiamen Haicang sub branch has redeemed the structural deposit on schedule 1.00
9 Industrial Bank Co.Ltd(601166) Xiamen Haicang structured deposit 300. Zoje Resources Investment Co.Ltd(002021) .1.132021.3.12 redeemed sub branch on schedule
10 China Galaxy Securities Co.Ltd(601881) securities company financial products 5 China Vanke Co.Ltd(000002) 021.1.132021.2.1 the limited company has been redeemed on schedule
11 China Galaxy Securities Co.Ltd(601881) securities company financial products 3 China Vanke Co.Ltd(000002) 021.2.4 2021.5.10 the limited company has been redeemed on schedule
12 China Merchants Bank Co.Ltd(600036) Xiamen branch bank financial product 3 China Vanke Co.Ltd(000002) 021.2.5 2021.3.22 has redeemed Zhenhai sub branch on schedule
13. China China Construction Bank Corporation(601939) Xiamen seven day call deposit 6 China Vanke Co.Ltd(000002) 021.2.8 2021.2.18 the principal and interest of Haicang sub branch have been recovered on schedule
14 China Merchants Bank Co.Ltd(600036) Xiamen branch bank financial product 200.00 redeemed with Zhenhai sub branch redeemed on February 10, 2021
15 China Industrial And Commercial Bank Of China Limited(601398) Haicang structured deposit 3 China Vanke Co.Ltd(000002) 021.2.242021.5.25 has redeemed Xinyang sub branch on schedule
16 Xiamen International Bank Xiamen structured deposit 2 China Vanke Co.Ltd(000002) 021.3.9 2021.6.12 has redeemed Jiahe sub branch on schedule
17 China Galaxy Securities Co.Ltd(601881) securities company financial products 3 China Vanke Co.Ltd(000002) 021.3.102021.6.21 the limited company has been redeemed on schedule
18 China Industrial Securities Co.Ltd(601377) Co., Ltd. financial products 1 China Vanke Co.Ltd(000002) 021.5.262021.8.23 the company has been redeemed on schedule
19 China Galaxy Securities Co.Ltd(601881) securities company financial products 3 China Vanke Co.Ltd(000002) 021.6.4 2021.6.28 the limited company has been redeemed on schedule
20 Xiamen International Bank Xiamen structured deposit 2 China Vanke Co.Ltd(000002) 021.6.172021.9.22 has redeemed Jiahe sub branch on schedule
21 China Industrial Securities Co.Ltd(601377) Co., Ltd. financial products of securities companies 2 China Vanke Co.Ltd(000002) 021.7.7 202112.22 have been redeemed on schedule
Shanghai Pudong Development Bank
22 Co., Ltd. Xiamen structured deposit 15 Shenzhen Zhongheng Huafa Co.Ltd(000020) 21.9.1 202110.8 has been redeemed on schedule branch
23 Xiamen International Bank Xiamen structured deposit 3 China Vanke Co.Ltd(000002) 02100
